| NAV | $10.59 | Daily Change | $0.18 | 1.73% |
| Market Price | $10.61 | Daily Change | $0.19 | 1.82% |
Manufacturing genomic medicines is cumbersome, but new techniques using donated cells are more scalable and could slash production costs by 95%, potentially facilitating broader adoption.1
Recent regulatory approvals have helped genomic medicines gain momentum. Sales of genomic medicines are forecast to increase at a 47% compound annual growth rate from 2022-2028.2
GNOM provides global exposure to emerging areas within the Health Care sector, at the intersection of science and technology.
1International Society for Cell and Gene Therapy, Feb 2019
2Evaluate Pharma, Nov 2023
| Inception Date | 04/05/19 |
| Total Expense Ratio | 0.50% |
| Net Assets | $96.63 million |
| NAV | $10.59 |
The Global X Genomics & Biotechnology ETF (GNOM) seeks to invest in companies that potentially stand to benefit from further advances in the field of genomic science, such as companies involved in gene editing, genomic sequencing, genetic medicine/therapy, computational genomics, and biotechnology.
The Global X Genomics & Biotechnology ETF (GNOM) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Solactive Genomics Index.
| 30-Day SEC Yield | -0.18% |
| Distribution Frequency | Semi-Annually |
| NAV | $10.59 | Daily Change | $0.18 | 1.73% |
| Market Price | $10.61 | Daily Change | $0.19 | 1.82% |
|
Cumulative Returns (as of 04/30/24)
|
1 Month | 6 Months | YTD | 12 Months | 24 Months | Since Inception | Inception Date |
|---|---|---|---|---|---|---|---|
| Return GNOM | -13.29% | 11.20% | -14.87% | -19.59% | -22.77% | -35.43% | 04/05/19 |
|
Returns (as of 05/10/24)
|
Return GNOM | Return Index |
|---|---|---|
| Since Inception | -31.76% | -29.91% |
| 12 Months | -14.66% | -13.81% |
| 24 Months | -13.04% | -12.16% |
| Last 60 Trading Days | -7.36% | -7.16% |
| Last 75 Trading Days | -4.91% | -4.67% |
|
Monthly Returns (through 05/10/24)
|
Return GNOM | Return Index |
|---|---|---|
| May 2024 | 5.68% | 5.75% |
| Apr 2024 | -13.29% | -13.23% |
| Mar 2024 | -5.41% | -5.20% |
| Feb 2024 | 11.62% | 11.55% |
| Jan 2024 | -7.01% | -6.90% |
| Dec 2023 | 11.12% | 11.12% |
| Nov 2023 | 17.53% | 17.71% |
| Oct 2023 | -12.70% | -12.66% |
| Sep 2023 | -9.53% | -9.44% |
| Aug 2023 | -8.41% | -8.28% |
| Jul 2023 | 1.22% | 1.27% |
| Jun 2023 | -0.83% | -0.71% |
| May 2023 | -0.40% | 0.01% |
| Apr 2023 | -0.32% | -0.36% |
| Mar 2023 | -2.40% | -2.28% |
| Feb 2023 | -7.07% | -7.73% |
| Jan 2023 | 7.02% | 7.13% |
| Dec 2022 | -5.87% | -5.89% |
| Nov 2022 | 2.37% | 2.43% |
| Oct 2022 | 4.96% | 5.00% |
| Sep 2022 | -9.67% | -9.59% |
| Aug 2022 | -2.51% | -2.52% |
| Jul 2022 | 16.09% | 16.12% |
| Jun 2022 | 2.26% | 2.22% |
| May 2022 | -6.13% | -5.96% |
Total returns take into account management, administration and fees and other costs automatically deducted from the fund's assets. Before investing, you may read the prospectus in the “FEES AND EXPENSES” section for more details.
| Net Assets (%) | Ticker | Name | Country | SEDOL | Market Price ($) | Shares Held | Market Value ($) |
|---|---|---|---|---|---|---|---|
| 4.86 | TECH | BIO-TECHNE CORP | United States | BSHZ3Q0 | 81.97 | 57,315 | 4,698,110.55 |
| 4.46 | NTLA | INTELLIA THERAPEUTICS INC | United States | BYZM6C2 | 25.42 | 169,364 | 4,305,232.88 |
| 4.35 | MRNA | MODERNA INC | United States | BGSXTS3 | 125.67 | 33,448 | 4,203,410.16 |
| 4.26 | NTRA | NATERA INC | United States | BYQRG48 | 103.33 | 39,790 | 4,111,500.70 |
| 4.05 | A | AGILENT TECHNOLOGIES INC | United States | 2520153 | 147.76 | 26,481 | 3,912,832.56 |
| 4.02 | QGEN | QIAGEN N.V. | United States | BMGBZP0 | 44.33 | 87,690 | 3,887,297.70 |
| 3.99 | SRPT | SAREPTA THERAPEUTICS INC | United States | B8DPDT7 | 131.70 | 29,303 | 3,859,205.10 |
| 3.99 | MYGN | MYRIAD GENETICS INC | United States | 2614153 | 24.93 | 154,621 | 3,854,701.53 |
| 3.97 | BNTX | BIONTECH SE-ADR | United States | BK6H543 | 92.72 | 41,331 | 3,832,210.32 |
| 3.93 | ALNY | ALNYLAM PHARMACE | United States | B00FWN1 | 149.89 | 25,319 | 3,795,064.91 |
| 3.77 | CRSP | CRISPR THERAPEUTICS AG | United States | BDHF4K6 | 55.65 | 65,427 | 3,641,012.55 |
| 3.69 | TXG | 10X GENOMICS INC-CLASS A | United States | BKS3RS7 | 26.97 | 132,304 | 3,568,238.88 |
| 3.61 | RCKT | ROCKET PHARMACEU | United States | BDFKQ07 | 23.09 | 151,060 | 3,487,975.40 |
| 3.58 | LEGN | LEGEND BIOTECH CORP-ADR | United States | BMX9K07 | 42.97 | 80,606 | 3,463,639.82 |
| 3.57 | ARWR | ARROWHEAD PHARMA | United States | BYQBFJ8 | 22.06 | 156,333 | 3,448,705.98 |
| 3.49 | RARE | ULTRAGENYX PHARM | United States | BJ62Z18 | 40.96 | 82,227 | 3,368,017.92 |
| 3.46 | ILMN | ILLUMINA INC | United States | 2613990 | 112.77 | 29,633 | 3,341,713.41 |
| 3.45 | RNA | AVIDITY BIOSCIENCES INC | United States | BMWHPY1 | 26.02 | 128,257 | 3,337,247.14 |
| 3.33 | BMRN | BIOMARIN PHARMAC | United States | 2437071 | 80.50 | 39,924 | 3,213,882.00 |
| 3.09 | VCYT | VERACYTE INC | United States | BFTWZY0 | 22.50 | 132,699 | 2,985,727.50 |
| 3.08 | 1548 HK | GENSCRIPT BIOTECH CORP | Hong Kong | BD9Q2J2 | 1.53 | 1,946,618 | 2,974,845.79 |
| 3.03 | BEAM | BEAM THERAPEUTICS INC | United States | BK6L288 | 24.02 | 121,933 | 2,928,830.66 |
| 2.01 | VRTX | VERTEX PHARM | United States | 2931034 | 429.93 | 4,521 | 1,943,713.53 |
| 1.88 | GILD | GILEAD SCIENCES INC | United States | 2369174 | 67.54 | 26,918 | 1,818,041.72 |
| 1.76 | SANA | SANA BIOTECHNOLOGY INC | United States | BMFJJ97 | 7.91 | 215,277 | 1,702,841.07 |
| 1.62 | VIR | VIR BIOTECHNOLOGY INC | United States | BK4PZ38 | 9.77 | 159,971 | 1,562,916.67 |
| 1.36 | CDNA | CAREDX INC | United States | BP3YM74 | 14.98 | 87,475 | 1,310,375.50 |
| 1.29 | RGNX | REGENXBIO INC | United States | BZ0G875 | 15.74 | 79,074 | 1,244,624.76 |
| 0.92 | PACB | PACIFIC BIOSCIEN | United States | B4N8MH9 | 1.93 | 461,771 | 891,218.03 |
| 0.85 | EDIT | EDITAS MEDICINE INC | United States | BZ8FPH3 | 5.71 | 144,497 | 825,077.87 |
| 0.82 | FLGT | FULGENT GENETICS INC | United States | BYQBFQ5 | 22.19 | 35,637 | 790,785.03 |
| 0.67 | CASH | United States | 1.00 | 644,548 | 644,547.61 | ||
| 0.63 | VERV | VERVE THERAPEUTICS INC | United States | BNKGXX2 | 6.22 | 97,339 | 605,448.58 |
| 0.58 | 4974 JP | TAKARA BIO INC | Japan | B03ML21 | 6.66 | 84,210 | 560,553.95 |
| 0.56 | ALLO | ALLOGENE THERAPEUTICS INC | United States | BFZNYB7 | 2.90 | 187,647 | 544,176.30 |
| 0.54 | CRBU | CARIBOU BIOSCIENCES INC | United States | BNYJR68 | 3.71 | 139,370 | 517,062.70 |
| 0.52 | LYEL | LYELL IMMUNOPHARMA INC | United States | BN6MB18 | 2.40 | 209,694 | 503,265.60 |
| 0.39 | TSVT | 2SEVENTY BIO INC | United States | BMTXV88 | 4.49 | 84,699 | 380,298.51 |
| 0.39 | QURE | UNIQURE NV | United States | BJFSR88 | 4.88 | 77,457 | 377,990.16 |
| 0.38 | PSTX | POSEIDA THERAPEUTICS INC | United States | BJ4SF41 | 2.81 | 129,769 | 364,650.89 |
| 0.36 | BLUE | BLUEBIRD BIO INC | United States | BBFL7S1 | 1.02 | 336,055 | 342,776.10 |
| 0.05 | E | SCILEX HOLDING RESTRICTED | United States | 9A80I96 | 0.20 | 226,071 | 45,491.05 |
| 0.00 | JAPANESE YEN | United States | 0.01 | -1 | -0.01 | ||
| -0.59 | OTHER PAYABLE & RECEIVABLES | United States | 1.00 | -568,090 | -568,089.60 |
| Sector | Weight (%) | |
|---|---|---|
| Health Care | 92.5 | |
| Energy | 7.5 |
Source: AltaVista Research, LLC
| Country | Weight (%) | |
|---|---|---|
| United States | 78.3 | |
| Italy | 7.5 | |
| Switzerland | 4.6 | |
| Netherlands | 4.1 | |
| Germany | 3.2 | |
| China | 1.8 | |
| Japan | 0.6 |
Source: AltaVista Research, LLC
| Return on Equity | -16.60% | |
| Weighted Avg. Market Cap | 16,496 M | |
| 2023 | 2024 | |
| Price-to-earnings | -15.00 | -17.80 |
| Price-to-book value | 2.70 | 3.25 |
Source: AltaVista Research, LLC
| Versus | Beta |
|---|---|
| S&P 500 | 1.22 |
| MSCI EAFE | 1.09 |
| MSCI Emg. Mkts | 0.93 |
| Standard Deviation | 30.70% |
Source: AltaVista Research, LLC
TERMS OF USE
Global X Brasil Gestora de Investimentos Ltda. (“Global X Brasil”) is an asset manager authorized by the Brazilian Securities and Exchange Commission (“CVM”), constituted in the form of CVM Resolution No. 21/2021. Investing involves risks. The material on this site is for informational purposes only and does not constitute investment advice, recommendation, offer or solicitation to buy or sell any securities, funds, or strategies to any person in any jurisdiction in which an offer, solicitation, purchase, or sale would be illegal under the securities laws of such jurisdiction. Opinions expressed here are subject to change without notice. Reliance upon the information contained in this material is at the sole discretion of the reader. No securities regulator has confirmed the accuracy of any information contained herein. Access to the information on this site or the use of the services or information provided herein is prohibited by any person or entity in any jurisdiction or country where such distribution or use is contrary to local law, rules, or regulation. Investment in index funds (ETFs) involves risks, including detachment from the benchmark index and related to the liquidity of shares in the secondary market. Investment funds managed by Global X Brasil use strategies that can result in significant equity losses for their quota holders. Global X Brasil, its partners and employees are exempt of responsibility for any damages resulting directly or indirectly from the use of the information contained on this website.
FOR EVALUATION OF THE PERFORMANCE OF AN INVESTMENT FUND, IT IS RECOMMENDED THE ANALYSIS OF AT LEAST 12 (TWELVE) MONTHS. INVESTMENT FUNDS DO NOT HAVE A GUARANTEE FROM THE ADMINISTRATOR, THE MANAGER, ANY INSURANCE MECHANISM OR CREDIT GUARANTEE FUND – FGC. INVESTMENTS IN FINANCIAL AND CAPITAL MARKETS ARE SUBJECT TO RISKS OF LOSS GREATER THAN THE TOTAL VALUE OF INVESTED CAPITAL. PAST PROFITABILITY DOES NOT REPRESENT A GUARANTEE OF FUTURE PROFITABILITY THE PROFITABILITY DISCLOSED IS NOT NET OF TAXES. READ THE PROSPECTUS, THE FORM OF COMPLEMENTARY INFORMATION, SHEET OF ESSENTIAL INFORMATION AND THE REGULATION BEFORE INVESTING. DESCRIPTION OF THE ANBIMA TYPE AVAILABLE IN THE FORM OF COMPLEMENTARY INFORMATION.